Pacira reported $10.3B in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Astellas Pharma JPY 1.44T 41.22B Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Cara Therapeutics USD 23.13M 2.2M Sep/2026
Coherus Biosciences USD 133.79M 72.25M Jun/2026
Heron Therapeutics USD 209.11M 20.73M Sep/2026
Ironwood Pharmaceuticals USD 225.99M 26.79M Sep/2026
J&J USD 56.35B 3.42B Sep/2026
Ligand Pharmaceuticals USD 608.23M 848.88M Sep/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Novo Nordisk DKK 208.7B 31.38B Jun/2026
Omeros USD 69.65M 26.53M Jun/2025
Pacira USD 10.3B 9.68B Sep/2026
Perrigo USD 2.4B 49.7M Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
Supernus Pharmaceuticals USD 711.21M 12.28M Sep/2026
Teva Pharmaceutical Industries USD 14.6B 842M Sep/2026
Xeris Pharmaceuticals USD 289.26M 14.51M Sep/2026
Zoetis USD 6.29B 63M Sep/2026